Exton, PA, United States of America

Jillian Dimuzio

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Immunome, Inc.. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jillian Dimuzio

Introduction

Jillian Dimuzio is a notable inventor based in Exton, Pennsylvania. She has made significant strides in the field of biotechnology, particularly in the development of treatments for viral infections. Her work is characterized by a commitment to advancing medical science and improving patient outcomes.

Latest Patents

Jillian holds a patent for an antibody cocktail against the SARS-CoV-2 spike protein. This innovative patent provides antibodies that are useful for treating SARS-CoV-2 infections in a subject. The patent also includes compositions comprising one or more antibodies, methods of treatment involving the administration of these antibodies, and kits that contain one or more antibodies.

Career Highlights

Jillian Dimuzio is currently employed at Immunome, Inc., where she continues to contribute to groundbreaking research and development in the field of immunotherapy. Her work at Immunome has positioned her as a key player in the fight against viral diseases, particularly in the context of the COVID-19 pandemic.

Collaborations

Jillian collaborates with esteemed colleagues, including Matthew K. Robinson and Pavel Nikitin. These partnerships enhance her research efforts and contribute to the overall success of her projects.

Conclusion

Jillian Dimuzio's innovative work in developing treatments for SARS-CoV-2 showcases her dedication to advancing medical science. Her contributions are vital in the ongoing battle against viral infections, and her patent reflects her commitment to improving healthcare solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…